PSA Test: More Harm Than Good?
Study: 1 Million Men Suffered Needless Treatment After Prostate Cancer Test
WebMD News Archive
PSA Benefit Smaller Than Supposed
In an editorial accompanying the study, Otis Brawley, MD, chief medical officer of the American Cancer Society, notes that two recent clinical trials of PSA screening argue against routine use of the test. A U.S. trial found no benefit; a European trial found some benefit but a very high rate of overdiagnosis.
The main problem, Brawley says, is that many early prostate cancers never will cause problems. Although PSA tests lead to prostate biopsies that find early prostate cancers, there's still no way to know which of these cancers are dangerous and which aren't.
Yet it's still common for men to be urged to get PSA tests by those who extol the benefits without ever mentioning the risks. They often learn of those risks long after they've undergone costly and adverse event-prone treatment.
"Many men who thought their lives were saved by being screened, diagnosed, and treated for localized prostate cancer are perplexed to learn that so few benefit," Brawley notes.
Watchful Waiting for Prostate Cancer
What if a man decides to get regular PSA tests, but does not undergo treatment if a low-risk cancer is detected?
That's a strategy called watchful waiting. It's more common in Europe than in the U.S. The basic strategy here is to defer surgery or radiation therapy and to have one's doctor keep a close eye on lower-risk prostate cancers.
Can it work? Martin Sanda, MD, director of the prostate cancer center at Beth Israel Deaconess Medical Center, and colleagues evaluated 342 men who deferred treatment for at least one year after prostate cancer diagnosis.
Half the men remained untreated for nearly eight years; the other half eventually opted for treatment an average four years after diagnosis. These men were compared with men who chose immediate treatment after diagnosis.
"Among those who held off on treatment, 98% survived. With immediate treatment, the rate of survival was 99%," Sanda tells WebMD. "That tells us the guys who held off treatment, if there was any downside in terms of prostate cancer survival, it was very small."